Spots Global Cancer Trial Database for nsclc, stage iii

Every month we try and update this database with for nsclc, stage iii cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab	NCT05757843	NSCLC, Stage II...	Signatera ctDNA... Durvalumab	18 Years -	Indiana University
Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients	NCT04680377	NSCLC, Stage II... Locally Advance...		18 Years -	University of Kansas Medical Center
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study	NCT04392505	Cancer Non Small Cell ... Non Small Cell ... NSCLC NSCLC, Stage II...	Durvalumab Inje...	18 Years -	Oslo University Hospital
To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC	NCT03130829	NSCLC Stage IV NSCLC, Stage II...	Oligo Fucoidan Placebo	20 Years -	Hi-Q Marine Biotech International, Ltd.
A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC	NCT05386888	NSCLC, Stage II...	GFH018 Toripalimab Paclitaxel Carboplatin Cisplatin Pemetrexed Thoracic Radiat... GFH018	18 Years -	Genfleet Therapeutics (Shanghai) Inc.
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab	NCT05757843	NSCLC, Stage II...	Signatera ctDNA... Durvalumab	18 Years -	Indiana University
A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China	NCT04830826	NSCLC, Stage I NSCLC, Stage II NSCLC, Stage II...	Surgeries	-	The First Affiliated Hospital of Guangzhou Medical University
Lung Cancer Registry	NCT04654364	Lung Cancer NSCLC Stage IV NSCLC, Stage II... SCLC, Extensive... SCLC, Limited S...		18 Years -	Arbeitsgemeinschaft medikamentoese Tumortherapie
SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC	NCT05177497	NSCLC, Stage II...	SHR-1701	18 Years -	Shanghai Chest Hospital
Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.	NCT05128630	NSCLC, Stage II...	Durvalumab	18 Years -	IRCCS Policlinico S. Matteo
Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab	NCT05027165	Oncology Biomarker NSCLC, Stage II... Durvalumab Chemoradiothera...	Non-interventio...	18 Years -	LMU Klinikum
Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.	NCT04202809	NSCLC, Stage II...	Durvalumab	18 Years - 74 Years	University Hospital, Essen
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC	NCT04585490	Non Small Cell ... NSCLC, Stage II... Nsclc	Durvalumab Carboplatin Pemetrexed Paclitaxel Cisplatin AVENIO ctDNA Su... Tremelimumab	18 Years -	Stanford University
Lung Cancer Registry	NCT04654364	Lung Cancer NSCLC Stage IV NSCLC, Stage II... SCLC, Extensive... SCLC, Limited S...		18 Years -	Arbeitsgemeinschaft medikamentoese Tumortherapie
Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer	NCT05718297	NSCLC, Stage II... ALK-rearrangeme...	Brigatinib Durvalumab	18 Years -	ETOP IBCSG Partners Foundation
SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC	NCT05177497	NSCLC, Stage II...	SHR-1701	18 Years -	Shanghai Chest Hospital
To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC	NCT03130829	NSCLC Stage IV NSCLC, Stage II...	Oligo Fucoidan Placebo	20 Years -	Hi-Q Marine Biotech International, Ltd.
Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities	NCT05311709	Lung Cancer NSCLC, Stage II... NSCLC Stage IV Lung Cancer Sta... Mutation Cancer Cancer, Lung	sotorasib	18 Years -	Vestre Viken Hospital Trust
Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer	NCT03999710	Non Small Cell ... Lung Cancer Nsclc NSCLC Stage II NSCLC, Stage II...	Radiation Thera... Durvalumab	18 Years -	Memorial Sloan Kettering Cancer Center
The Role of Microbiota on the Development of Lung Cancer	NCT03454685	NSCLC, Stage I NSCLC, Stage II NSCLC, Stage II... NSCLC Stage IV Healthy Subject...	without interve...	18 Years - 70 Years	Wuhan Union Hospital, China
Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.	NCT05128630	NSCLC, Stage II...	Durvalumab	18 Years -	IRCCS Policlinico S. Matteo
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study	NCT04392505	Cancer Non Small Cell ... Non Small Cell ... NSCLC NSCLC, Stage II...	Durvalumab Inje...	18 Years -	Oslo University Hospital
Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy	NCT04351256	NSCLC, Stage II...	Durvalumab Inje... Thoracic Radiot... Thoracic Radiot...	18 Years -	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC	NCT04952168	NSCLC, Stage II...	Almonertinib	18 Years -	Tongji Hospital

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: